Jun-Wei et al. [15] reported that SSBP2 promoter hypermethylation was found in 61.4% of prostate cancer cases, whereas none of the benign prostatic hyperplasia cases showed hypermethylation. Here, SSBP2 is linked to prostate carcinoma.